Skip to main content
PharmSpace

ACE inhibitors · Cardiovascular

Lisinopril

Zestril® · Prinivil®(brand names vary by market)

The ACE inhibitor that needs no activation, which matters in liver failure.

Illustration of Lisinopril as a tabletLIS

Mechanism

The only common ACE inhibitor that is active as given rather than a prodrug: no hepatic conversion step between the tablet and the effect.

Open the interactive pathway

Indications

  • Hypertension
  • Heart failure with reduced ejection fraction
  • Post myocardial infarction
  • Diabetic nephropathy

Formulations

Tablet

Dosing concepts

Hepatic impairment

Because it is not a prodrug, its effect does not depend on liver conversion; that is the one situation where the choice within the class is a real one.

Renal impairment

Renally cleared, so the starting dose falls as clearance does.

Concepts, not prescribing instructions. Practice numbers live in current references and local protocols.

Pharmacokinetics

Bioavailability
~25%, unaffected by food
Half-life
~12 h
Elimination
renal: Excreted unchanged; no hepatic metabolism at all
Protein binding
Negligible
Play with these concepts in the PK Lab

Adverse effects

  • Dry coughcommon
  • Hyperkalemiacommon & serious
  • Acute kidney injury when volume-depleteserious
  • AngioedemaseriousHigher reported rates in patients of African ancestry.

Contraindications & precautions

Contraindications

  • Pregnancy
  • Prior ACE inhibitor angioedema
  • Bilateral renal artery stenosis

Precautions

  • Renal impairment
  • Volume depletion
  • Concurrent potassium-raising drugs

Interactions

Monitoring

Creatinine and potassium

Baseline and after every change · 1 to 2 weeks after starting or increasing

Blood pressure

Effect

Counselling points

  • Once daily, with or without food.
  • Report a persistent dry cough; it is treatable by changing the drug.
  • Seek urgent help for any swelling of the face, lips or tongue.
  • Avoid potassium-containing salt substitutes.

Clinical pearls

  • No prodrug step and no protein binding makes it the most predictable member of its class, which is why it appears so often in trials.
  • Angioedema can appear after years of uneventful use. Duration of therapy is no reassurance at all.

References & review

  • Lisinopril product monograph (consult the current version for your market) (monograph)
  • Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. (reference-work)

Last reviewed 2026-08-16 · jurisdiction: global · drug information changes; verify against current references before practice use.